( MGI PHARMA Summarizes Data Presented a...)MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting,Health

MGI PHARMA Summarizes Data Presented at the

2007 American Society of Clinical Oncology (ASCO) Annual Meeting

--Dacogen(R) Activity in Older Patients with AML and in Refractory

ALL Patients Presented--

--Differentiation of the molecular interaction of Aloxi(R) with

the 5-HT3 Receptor Reported--

--Results of a Survival Analysis of Glioblastoma Patients Treated

with Multimodal Therapy, including Gliadel(R) Described--

--Survival Analysis of Irofulven in Second-Line HRPC Patients

Presented--

CHICAGO---June 4, 2007--MGI Pharma, Inc. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, today provided highlights of data presentations made during the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting. Dacogen (decitabine) for Injection was the subject of five posters including the presentation of efficacy data in older patients with acute myelogenous leukemia (AML) and activity observed in patients with refractory acute lymphocytic leukemia (ALL). Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) was the subject of two posters with one detailing the impact of multimodal therapy that included Gliadel implantation, followed by treatment with radiation and concurrent temozolomide plus rotational chemotherapy, on survival in patients with primary glioblastoma. A poster discussion provided updated response and survival data from a randomized phase 2 clinical trial of Irofulven (MGI 114; hydroxymethylacylfulvene) in hormone refractory prostate cancer (HRPC) patients who failed docetaxel treatment. In addition to two posters, Aloxi(R) (palonosetron

hydrochloride) Injection was the subject of a published abstract describing study results that differentiate the molecular interaction of Aloxi with the 5-HT3 receptor. These data provide new insight into the receptor binding mechanisms that may explain the
'"/>